Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099853 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 362
- Enrollment target
NCT00099853 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 362 participants.
The verdict
NCT00099853, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 362 participants
- Enrollment target
Study Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to pioglitazone in people with type 2 diabetes not at target blood glucose levels on either pioglitazone or rosiglitazone alone.
Interventions
- DRUG Placebo
- DRUG pioglitazone
- DRUG Vildagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099853
The ClinicalTrials.gov registry entry for NCT00099853 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00099853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099853 about?
NCT00099853 is a clinical study titled "Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes". Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to pioglitazone in people with typ...
What is the current status of trial NCT00099853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 362 participants. The study started on 2004-05. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00099853?
The interventions under investigation include: Placebo (DRUG), pioglitazone (DRUG), Vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00099853?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.